Qiming Venture Leads $17M Series A Round In Chinese Biotech Firm CureGenetics

Suzhou city, Jiangsu Province-based biotech firm CureGenetics Co., Ltd has raised a US$17 million series A round led by Qiming Venture Partners. CTS Capital and Ascendin Investment also participated in the round, according to a company announcement. Founded in 2016, CureGenetics aims to develop applications of gene-editing technology in medicines and molecular diagnostics that will contribute to treating easy-to-relapse or hard-to-treat cancers and genetic diseases. "We believe that the outstanding technology platform and the top-class talents will continue to help …

Qiming Venture Leads $17M Series A Round In Chinese Biotech Firm CureGenetics appeared first on China Money Network.

Read the original article: China Money Network